CAR T-Cell Therapy: The Sticker Price Is Just for Openers

Tony Hagen @oncobiz
Published: Tuesday, Jun 12, 2018
The cost of a dose of medicine is generally thought to include just the pills or the fluid in the vial, but CMS has proposed a different way to handle payment for chimeric antigen receptor (CAR) T-cell therapy, one that the medical and manufacturing community thinks is unworkable. Although these agents' prices reach close to 0,000, they still reflect just the reengineered white blood cells, not all the ancillary elements of care, speakers testified at a recent hearing on CMS pricing policy.

CAR T-cell candidates are the “sickest of the sick,” and the amount of time they spend in the hospital could add substantial amounts to the overall cost of care; therefore, those costs of care cannot be handled as a fixed cost, speakers said.

Figure. Multiple Steps in Different Locations are Required for CAR T-cell Preparation

Further, they said, the care of CAR T-cell–eligible patients involves numerous medical entities and providers. According to those who testified, CMS’ wording of Q codes for CAR T-cell therapy resembles an attempt at bundling care that would amount to a compliance nightmare for administrators. “Our system is not set up to separate those kinds of things,” said Aaron D. Chrisman, MHA, MBA, director of stem cell transplant and cellular therapy administration at University of Chicago Medicine in Illinois.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x